Although findings from a large retrospective study supports these positive effects of taking a GLP-1, it’s unclear whether ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the company has received final approval from the US Food & Drug ...

FRANKFURT (Reuters) -Swiss drugmaker Novartis met third-quarter profit forecasts on Tuesday, as fast growth of newer drugs offset a sharp slowdown in blockbuster heart drug Entresto as it comes under ...

Novartis has started to feel the squeeze from generics to its top-selling drug, heart therapy Entresto. | Novartis has ...

A report details "deviations" during manufacturing of more than 135,000 packages, which could possibly contribute to other ...

Building on earlier studies showing its benefits for type 2 diabetes, a new study has revealed the experimental drug IC7Fc ...

Shares of Cytokinetics, which targets medicines for specialty heart diseases, have jumped about 69% over the past three months and are up 31% year to date.

USA: A new drug-eluting balloon (DEB) may offer a safer and equally effective alternative to conventional metallic stents for ...

Results from the first randomized clinical trial in the United States to compare a sirolimus-eluting balloon (DEB) to control ...

An international study involving Australian scientists has identified a potential new drug that may protect against both type 2 diabetes and heart disease by lowering cholesterol and reducing ...

Which is the point of generic drugs. They’re brilliant pharmaceutical representations of what’s true in all walks of ...